Acurx Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
ACXP$1.060.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
AS OF DECEMBER 31, 2023 and 2022
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · December 31, | ||||||
| · 2023 · 2022 | ||||||
| · · · · | ||||||
| ASSETS | | | ||||
| | | | | | | |
| CURRENT ASSETS · · | ||||||
| Cash | | $7,474,188 | | $9,111,751 | ||
| Other Receivable | | | 129,159 | | | — |
| Prepaid Expenses | | 105,776 | | 264,955 | ||
| TOTAL ASSETS | | $7,709,123 | | $9,376,706 | ||
| | | | | | | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | | | ||||
| | | | | | | |
| CURRENT LIABILITIES | | | | |||
| Accounts Payable and Accrued Expenses | | $3,042,438 | | $2,061,685 | ||
| TOTAL CURRENT LIABILITIES | | 3,042,438 | | 2,061,685 | ||
| | | | | | | |
| TOTAL LIABILITIES | | 3,042,438 | | 2,061,685 | ||
| | | | | | | |
| COMMITMENTS AND CONTINGENCIES | | | ||||
| | | | | | | |
| SHAREHOLDERS' EQUITY | | | | | | |
| Common Stock; $.001 par value, 200,000,000 shares authorized, 14,468,229 and 11,627,609 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | | 14,468 | | 11,628 | ||
| Additional Paid-In Capital | | 57,871,070 | | 45,944,478 | ||
| Accumulated Deficit | | (53,218,853) | | (38,641,085) | ||
| | | | | | | |
| TOTAL SHAREHOLDERS’ EQUITY | | 4,666,685 | | 7,315,021 | ||
| | | | | | | |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | | $7,709,123 | | $9,376,706 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.